Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
- 1 November 1999
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (11) , 3586-3595
- https://doi.org/10.1200/jco.1999.17.11.3586
Abstract
PURPOSE: To determine the maximum-tolerated dose (MTD) and pharmacologic behavior of ISIS 3521 (ISI 641A), an antisense phosphorothioate oligonucleotide to protein kinase C-alpha. PATIENTS AND METH...Keywords
This publication has 25 references indexed in Scilit:
- The Protein Kinase C Activator, Phorbol Ester, Elicits Disparate Functional Responses in Androgen-Sensitive and Androgen-Independent Human Prostatic Cancer CellsBiochemical and Biophysical Research Communications, 1998
- Characterization and Modulation of Immune Stimulation by Modified OligonucleotidesAntisense and Nucleic Acid Drug Development, 1997
- Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 MiceAntisense and Nucleic Acid Drug Development, 1997
- BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 1997
- Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley ratsToxicology, 1997
- Progress in Antisense Oligonucleotide TherapeuticsAnnual Review of Pharmacology and Toxicology, 1996
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Involvement of the α Isoenzyme of Protein Kinase C in the Growth Inhibition Induced by Phorbol Esters in MH1C1 Hepatoma CellsBiochemical and Biophysical Research Communications, 1994
- Therapeutic Applications of OligonucleotidesAnnual Review of Pharmacology and Toxicology, 1992
- The molecular heterogeneity of protein kinase C and its implications for cellular regulationNature, 1988